Axsome Therapeutics Inc’s recently made public that its Officer Herriot Tabuteau acquired Company’s shares for reported $2.95 million on Nov 05 ’25. In the deal valued at $135.69 per share,21,775 shares were bought.
Then, TABUTEAU HERRIOT sold 91,705 shares, generating $12,136,240 in total proceeds. Upon selling the shares at $132.34, the Chief Executive Officer now owns 7,229 shares.
Before that, TABUTEAU HERRIOT sold 50,459 shares. Axsome Therapeutics Inc shares valued at $6,750,910 were divested by the Chief Executive Officer at a price of $133.79 per share. As a result of the transaction, TABUTEAU HERRIOT now holds 7,229 shares, worth roughly $1.01 million.
B. Riley Securities initiated its Axsome Therapeutics Inc [AXSM] rating to a Buy in a research note published on October 01, 2025; the price target was $179. Oppenheimer started covering the stock on June 03, 2025. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock jump 1.31% to $139.61. Over the last five days, the stock has gained 3.47%. Axsome Therapeutics Inc shares have risen nearly 53.93% since the year began. Nevertheless, the stocks have risen 65.00% over the past one year. While a 52-week high of $141.36 was reached on 11/11/25, a 52-week low of $75.56 was recorded on 01/10/25.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 137.01, which if violated will result in even more drops to 134.41. On the upside, there is a resistance level at 142.20. A further resistance level may holdings at 144.79.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-10-31, growing by 0.22 million shares to a total of 3.6 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 3.38 million shares. There was a rise of 6.2%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 07, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $200 price target.
